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Abstract: This study evaluated the technological feasibility of producing a semipurifi ed 
extract of guaraná (Paullinia cupana Kunth, Sapindaceae) in tablet form, using a direct-
compression process. Maltodextrin and gum arabic were used to produce the extract 
microparticles, in order to protect the microparticles against such factors as temperature, 
oxidation, and humidity. Using pharmacopoeial methodologies, technological and 
physicochemistry tests (determination of residual moisture, of bulk and tapped density, 
Hausner ratio, compressibility and compactibility index, appearance, mean weight, 
hardness, friability, disintegration time, determination of EPA amount in tablets and in vitro 
release profi le) were conducted. The formulation containing 200 mg of microparticles, 
170 mg microcrystalline cellulose, and 10 mg lactose gave the best results in terms of 
hardness (116 N), friabilility (0.28%), mean weight (0.3821 g), and disintegration time 
(25 min) for a tablet designed for oral administration. The results met pharmacopoeial 
specifi cations, and the tablets are suitable for oral administration.
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Introduction
 A dosage form is developed in several stages, 
including studies of pre-formulation and the formulation 
itself. These stages consist of physical, chemical, 
physicochemical, and biological analyses of all materials, 
including the drug used in the preparation of the product, 
as well as the anatomical and physiological characteristics 
of the route of administration and absorption, and fi nally 
the development of the pharmaceutical form (Ansel et al., 
2000; Lachman et al., 2001; Aulton, 2007).
 Some studies with phytopharmaceuticals aim 
to develop a suitable product for industrial use and 
further therapeutic application (Couto et al., 2012). 
Alves et al. (2011) investigated the feasibility of a co-
processing technique for improving the manufacturing 
properties of extracts obtained from Maytenus ilicifolia 
(Schrad.) Planch., Celastraceae, and Cassia angustifolia 
Vahl, Fabaceae, in order to obtain tablets containing a 
high concentration of these extractive solutions. The 
spray-drying technology is an attractive and promising 
alternative for the development of intermediate 
phytopharmaceutical products (Bruschi et al., 2003; 
Bruschi et al., 2006; Dota et al., 2011; Couto et al., 
2012).
 The oral route is most often used in drug 
administration and is best accepted by patients. However, 
it is not always the most appropriate for administration 
of pharmaceuticals, since poorly soluble drugs may 
not be completely absorbed. Thus, in developing a new 
formulation, attention must be given to factors that 
improve the drug delivery in the gastrointestinal tract, 
including several related to the formulation: particle size, 
disintegration time, dissolution, the presence of hydrophobic 
and/or hydrophilic excipients, physicochemical properties, 
and other drug characteristics (Viana et al., 2006).
 Considering that poorly soluble drugs can 
be readily absorbed if suitable excipients are used, 
the formation of microparticles can further enhance 
the availability of the drug for absorption in the 
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gastrointestinal tract. The direct compression (DC) 
process is ideal for industrial-scale production of tablets 
(McCormick, 2005), and is suitable for substances that 
have free-flowing properties of cohesion and that can 
be compressed directly, without wet or dry granulation 
(Lachman et al., 2001). However, relatively few drugs 
can be compressed without prior granulation (Prista et 
al., 1995; Ansel et al., 2000; Yuan & Wu, 2001). Thus, in 
DC the excipients used must have appropriate properties 
of flow and compressibility (Palacios, 2000). The 
advantages of DC include speed, ease of manipulation, 
and reduced loss of the active ingredient. The method 
can be used with compounds that are unstable in humid 
and high-temperature conditions, and reduces the risks 
of contamination and oxidation, increases productive 
capacity, and is economical (Prista et al., 1995; Ansel 
et al., 2000; Palacios, 2000; Lachman et al., 2001).
 Studies of the extract and semipurified fractions 
of guaraná by Audi & Mello (2000), Otobone et al. 
(2005), Otobone et al. (2007), and Roncon et al. (2011) 
demonstrated the pharmacological properties of the 
lyophilized extract (EBPC) and semipurified fractions 
(EPA and EPB) after acute or chronic oral administration 
in rats. One of the properties is an antidepressive effect, 
comparable to imipramine; cognition testing in the 
Morris water maze demonstrated that the EPA fraction 
has an antimobility effect, suggesting an antidepressant 
effect as observed with EBPC. EPA is orally active and 
has a panicolytic effect involving the serotonergic and 
dopaminergic systems. 
 Therefore, EPA can be useful in treating mood 
disorders such as panic disorder. Condensed tannins, 
which were isolated from the EPA fraction by Yamaguti-
Sasaki et al. (2007), may be responsible for this activity, 
since Johnston & Beart (2004) showed that flavonoids can 
cross the blood-brain barrier and may act on the central 
nervous system. The promising activity of EPA encouraged 
us to attempt to develop the best technological features 
of this fraction, because its hygroscopic and electrostatic 
characteristics make it difficult to weigh accurately, 
and it is subject to degradation, mainly by oxidation. 
The need to protect this fraction led to an evaluation of 
microencapsulation as an alternative (Lachman et al., 
2001; Bruschi et al., 2003). EPA also has poor solubility, 
suggesting the addition of excipients that facilitate 
dispersion and solubility.
 The objective of this study was to develop and 
characterize tablets containing microparticles of EPA for 
oral administration. This is a monolithic system, where the 
asset is microencapsulated to protect it from degradation.
Material and methods
Material
 The following materials were used: 
microcrystalline cellulose (FMC BioPolymer, 
Philadelphia, PA, USA), lactose (Reagen, Rio de 
Janeiro, RJ, Brazil), gum arabic (Synth, Diadema, São 
Paulo, SP, Brazil), maltodextrin (Aldrich, St. Louis, 
MO, USA), acetonitrile, methanol, trifluoroacetic acid, 
acetone, ethyl acetate (JT Baker, Mexico City, Mexico), 
and ultrapure water (Milli-Q gradient, Millipore, 
Billerica, MA, USA).
Preparation of guaraná semipurified extract
 Seeds of Paullinia cupana Kunth, Sapindaceae 
(guaraná) were obtained from the municipality of Alta 
Floresta, Mato Grosso, Brazil. A voucher specimen was 
deposited in the Herbarium, Department of Biology, 
State University of Maringá under number HUEM 9065. 
The plant was identified by Professor Dr. Cássia Mônica 
Sakuragui. An extract was prepared in an acetone:water (7:3, 
v/v) 10% (w/v) solution by turbo extraction (UTC115KT 
Ultra-Turrax, Ika Works, Wilmington, NC, USA). The 
organic solvent was removed by a rotary evaporator under 
low pressure, and the material was lyophilized to yield the 
crude extract [EBPC; patent pending PI0006638-9 (Audi 
& Mello, 2000)]. EBPC was partitioned with ethyl acetate, 
resulting in an ethyl-acetate fraction (EPA), with a yield 
of 9.23% (w/w) relative to the dried seeds of guaraná 
(Antonelli-Ushirobira et al., 2010).
Preparation of microparticles containing EPA
 Microparticles containing EPA were produced 
using a spray dryer (Mini Spray Dryer, Büchi B-191, 
Switzerland), with inlet temperature of 190 °C, 80% 
aspiration, pressure of 2 bars, 6% pumping, and spray 
nozzle with orifice diameter of 0.7 mm. The dispersion was 
prepared with 10% (w/v) total solids of a mixture of gum 
arabic (GA) and maltodextrin (MD) (1:1, w/w) in water, 
and EPA, corresponding to 80% polymers and 20% EPA. 
Initially, the polymer mixture (GA, MD) was dispersed in 
water, and EPA was dispersed in 10% ethanol. The EPA 
and the polymer mixture were stirred separately (20 min), 
and the EPA solution was added to the polymer dispersion, 
stirred for 5 min at room temperature, and dried in the spray 
dryer. The resulting dried products were collected and kept 
in the dark and protected from rehydration in desiccation 
chamber at room temperature until further tests. The 
choice of an appropriate formulation of microparticles, 
and its development and characterization will be reported 
separately (Klein, 2012).
Physical and mechanical properties of microparticles
 Determination of residual moisture
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 To estimate the moisture content of spray-dried 
microparticles containing EPA, an aliquot of 3.0 g of 
sample was dried at 105 ºC for 30 min in an Ohaus-MB 
200 infrared analytical balance. At least three replicates 
were performed, to estimate the inherent variability of the 
analysis.
 Determination of bulk and tapped density
 The bulk and tapped densities of microparticles 
containing EPA were determined according to the 
methodology proposed by Guo et al. (1985) and Cardoso 
(2002). A sample of approximately 10 g was placed in a 
previously weighed cylinder with a capacity of 50 mL. 
The tapped density was determined using a compression 
volumeter (Erweka® SVM 12, Heusenstamm, Germany). 
The powder was subjected to 1250 falls, according to 
DIN 53 194. The analysis was performed in at least three 
replicates, and the bulk density (db) and tapped density 
(dc) were calculated by equations (1) and (2) (Lachman, 
2001; Aulton, 2007), respectively:
   db =  Ma                            Equation (1)
          Vb   
             dc =  Ma                            Equation (2)
                      Vc
     
 Where: Vb: bulk volume, Vc: compressed 
volume.
 Determination of Hausner ratio, compressibility 
and compactibility index
 The sample used in the previous experiment 
was used to determine the Hausner ratio (HR), 
compactibility, and compressibility indexes, according 
to the methodology of Guo et al. (1985) and Cardoso 
(2002). The Hausner ratio was determined from the 
ratio between the bulk and tapped densities, according 
to equation (3):
                 HR =  dc                         Equation (3)
                           db
     
 The compressibility index (CI) was determined 
according to equation (4):
                                Equation (4)
 
 Where: dc: tapped density (g/mL); db: bulk 
density (g/mL).
 The compactibility (C) was calculated by the 
difference between the volumes at 10 (V10) and 500 
falls (V500) by volume of compression, according to 
equation (5), using about 10 g of powder. The results were 
extrapolated to a mass of 100.0 g, obtaining the volume 
(mL) after 10 and 500 falls.
   C = V10 - V500         Equation (5)
Preparation and characterization of tablets containing 
EPA microparticles
 During the development of tablets containing 
the microparticles, different formulations were tested 
(Table 1). The components of the tablet formulation 
were mixed in a glass mortar, and geometric dilutions 
of the powder were made.
 Tablets were produced by direct compression in 
a compression machine (FELLC Compact 10, São Paulo, 
SP, Brazil), using a 10 mm round punch. Samples from 
different batches were individually weighed and placed 
in the compression chamber. For each formulation (Table 
1), the compressive force was adjusted according to the 
properties of the material. The compression force of the 
machine was manually adjusted, i.e., for each material the 
behavior at a particular applied force was observed. To 
obtain the tablets, the machine engine was not engaged, 
so each form of the solid dosage was obtained individually 
by manual rotation of the punch. After compression, the 
formulations were collected and stored away from light and 
rehydration (in desiccation chamber) at room temperature 
until further analysis.
 Appearance
 The macroscopic characteristics of each 
formulation and pharmaceutical dosage form were 
observed, including the geometric shape, appearance, 
color, and presence of foreign material or particles.
100)( x
dc
dbdcCI 
Table 1. Composition of the formulations tested for the development of tablets containing EPA microparticles.
Formulation Microparticles (mg) Microcrystalline cellulose (mg) Lactose (mg) Final tablet weight (mg)
1 400 0 0 400
2 200 25 75 300
3 200 90 10 300
4 200 140 10 350
5 200 170 10 380
I dc    dbdc
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 Mean weight
 The mean weight of each batch of tablets 
was determined using the methodology described in 
the Brazilian Pharmacopoeia (2010), using a range of 
tolerance of 5% for tablets with a mean weight above 
250.0 mg. Twenty tablets were weighed individually, 
and the mean weight was determined.
 Hardness
 The hardness of the tablets was determined using 
an ERWEKA® durometer (Heusenstamm, Germany). Ten 
tablets were evaluated for each formulation (Brazilian 
Pharmacopoeia, 2010).
 Friability
 According to the procedure recommended in 
the Brazilian Pharmacopoeia (2010), twenty units were 
weighed and submitted to an Ethics® friability test (São 
Paulo, SP, Brazil). After 100 rpm for 5 min, the tablets were 
weighed again. The difference between the initial and final 
weights represents the friability (FR), as estimated by the 
percentage of powder lost.
 Determination of EPA amount in tablets
 For determination of the EPA concentration 
in the tablets, the quantification of chemical markers 
for EPA (catechin and epicatechin) was performed by 
High Performance Liquid Chromatography (HPLC) as 
developed by Klein et al. (2012). Briefly, chromatographic 
separation: Phenomenex® Synergi POLAR-RP 80A 
stainless-steel analytical column (250 mm×4.6 mm, 4 
μm) and a Phenomenex C18 guard cartridge system (4 
μm, 4.6 mm×20 mm). The mobile phases were: Phase A, 
water plus 0.05% TFA and Phase B, methanol:acetonitrile 
(25:75) plus 0.05% TFA, the gradient system established: 
0 min, 80:20 (A:B); 20 min, 74:26 (A:B); 21 min, 80:20 
(A:B); 24 min, 80:20 (A:B), 280 nm wavelength and 0.5 
mL/min. For each formulation, at least three replicates 
were analyzed and the content of each EPA marker was 
determined in relation to the respective final formulation, 
using a calibration curve previously obtained using a 
catechin or epicatechin standard.
 Evaluation of disintegration time
 The disintegration test was performed following 
the method established by the Brazilian Pharmacopoeia 
(2010), using an Ethics® disintegration tester (São Paulo, 
SP, Brazil). In this test, a time limit of 30 min was used for 
the tablets.
 In vitro release profile of EPA from formulations
 The release profile of active substances (catechin 
and epicatechin) from the tablets was determined in a USP 
Apparatus 4 flow-through cell dissolution tester (SOTAX 
Smart AT7®, USA), using distilled water as the dissolution 
medium, at 37 °C, collection volume 5 mL, and flow 8 
mL/min, with 22.6-mm cells. The analysis was carried out 
with at least three replicates. To prepare the sample for 
HPLC analysis, the volume was subjected to solid-phase 
extraction (SPE Strata C18-E) and completed to 10 mL in 
a volumetric flask. The catechin and epicatechin markers 
were quantified according to Klein et al. (2012).
Results and Discussion
 The flow of powder during manufacturing 
dictates the quality of the product in terms of its weight 
and uniformity of content. However, the flow profile 
of a powder is complex and multidimensional, and 
depends on many characteristics of the powder. To 
address this multidimensional problem, several flow 
measurements are performed in order to obtain a more 
coherent flow classification (Alves et al., 2011).
 The processing of plant extracts with 
pharmaceutical excipients could lead to the formation of 
materials with superior mechanical characteristics that are 
suitable for direct compression. The spray-drying technique 
has been used to obtain dried extracts with improved 
technological characteristics and a higher concentration of 
substances with biological activity (Oliveira & Petrovick, 
2010). Thus, this technique was chosen to produce the 
microparticles containing the EPA semipurified extract, 
using GA and MD as polymers.
 The moisture content of the EPA microparticle 
powder was determined as 5.16%±0.75. The bulk and 
tapped density were 0.3283±0.0084 and 0.4221±0.0136 
g/mL, respectively. Thus, the Hausner ratio (HR) is 
1.28±0.02, and high cohesiveness and internal friction 
are characteristics of powders that possess HR greater 
than 1.25 (USP, 2007). The compressibility index 
(CI) and rate of C are 22.18±1.48% and 7.33±2.36 
mL, respectively. The CI indicates very poor flow and 
compressibility characteristics (USP, 2007).
 In general, powders with a HR less than 1.25, 
CI less than 18% compactibility, and C less than 20 
mL are easily compressible (Lachman et al., 2001; 
Aulton, 2007). Therefore, the EPA microparticle 
powder is not easily compressible. Because of this 
difficulty, other pharmaceutical compression excipients 
(microcrystalline cellulose and lactose for direct 
compression) were used to assist in the preparation of 
tablets containing the EPA microparticles.
 When developing a new formulation, all 
the physical characteristics and physicochemical 
Development of tablets containing semipurified extract of guaraná (Paullinia 
cupana)
Traudi Klein et al.
Rev. Bras. Farmacogn. Braz. J. Pharmacogn. 23(1): Jan./Feb. 2013190
characteristics of the powders, including particle 
size, disintegration time, dissolution, presence of 
hydrophobic and/or hydrophilic excipients, physical 
and chemical properties, and other characteristics of 
the drug are determining factors in obtaining tablets 
that are suitable for administration (Viana et al., 2006; 
Alves et al., 2011).
 First, the EPA microparticles were compressed 
directly, with no added excipients (Formulation 1). 
These tablets showed a hardness value of 55 N, but 
did not pass the friability test (Table 2) (Brazilian 
Farmacopoeia, 2010).
 In order to improve the flow properties of the EPA 
microparticles, which was necessary to achieve adequate 
flow while feeding the machine for filling and compressing 
the compression matrices (Aulton, 2007) and to decrease 
the friability of the tablets, lactose and microcrystalline 
cellulose were used as excipients, in different proportions.
 These adjuvants were selected to provide 
certain attributes in order to obtain tablets with 
good physical characteristics and physicochemical 
properties. Cellulose is one of the materials most 
commonly used as a pharmaceutics adjuvant, and 
improves the flow characteristics of the powder and 
hence the uniformity of the final weight of the dosage 
(Toller & Schmidt, 2005). Lactose is also widely used 
in the pharmaceutical industry as a diluent in the 
production of tablets. The development of spray-dried 
lactose, with improved characteristics of compactibility 
and flow, has revolutionized the production of tablets, 
because it was one of the first excipients with a specific 
application to direct compression processes of solid 
oral forms (Toller & Schmidt, 2005). Although various 
raw materials are available, cellulose and lactose are 
still widely used, since they differ in particle size, 
degree of mixing, flow, density and other properties 
that allow the confection of dosage forms with suitable 
physicochemical characteristics and reproducible 
production on any scale (Toller & Schmidt, 2005). In 
this study, the proportions between these adjuvants were 
determined according to practical production needs. 
A lubricant was not used because preliminary tests 
indicated no adhesion of the powder on the punches.
 The analysis showed that Formulation 2 was 
not adequate because the tablets showed a lack of 
cohesion between particles. Formulation 3 displayed a 
hardness of 493 N, but did not pass the friability test; 
while formulation 4 showed a hardness of 491 N and a 
10.08% loss in the friability test (Table 3). On the other 
hand, Formulation 5 showed suitable characteristics, 
particularly hardness and friability, as shown by the 
test results in Table 3.
 The mean weight of the tablets was appropriate, 
and all tablets were within±5% of the mean, as specified 
by the Brazilian Pharmacopoeia (2010). This standard 
allows no more than two units outside the specified limits, 
in relation to the mean weight. The low relative standard 
deviations indicated that the improved flowability of the 
powder made it appropriate for machine feeding (Alves et 
al., 2011).
Table 2. Results of hardness and friability analyses of the tablet 
formulations.
Tablets Hardness (N)±SD Friability (%)
Formulation 1 55±2.51 n.d.
Formulation 2 n.d. n.d.
Formulation 3 493±2.08 n.d.
Formulation 4 491±3.05 10.08
Formulation 5 116±3.13 0.28
n.d: not detectable; SD: standard deviation
 Tablets must be sufficiently hard to resist 
breakage during packaging, transport, or conventional 
handling (Ansel et al., 2000; Elkhalifa et al., 2009). 
However, tablets should be able to dissolve or disintegrate 
after they are properly administered, or be broken with 
the fingers if a partial dose is needed. Friability is the 
lack of resistance to abrasion, when subjected to the 
mechanical action of specific equipment. The friability 
determined for the tablets made from Formulation 5 was 
less than 1.5%, within the acceptable limit prescribed by 
the Brazilian Pharmacopoeia (2010). This ensured that the 
tablets were produced with appropriate characteristics of 
cohesion between the particles, to withstand the impact of 
manipulation and transport. 
 Regarding the content of the active ingredient, all 
the formulations were within the limits set by the Brazilian 
Pharmacopoeia (2010) to ensure a suitable dose (Viana et 
al., 2006; Alves et al., 2011).
 With respect to disintegration, Formulation 5 
disintegrated within 30 min. A 30-min time limit is used as 
a general criterion for testing the disintegration of tablets, 
unless otherwise specified (Brazilian Pharmacopoeia, 
2010).
 The development of immediate-release tablets 
that contain a high proportion of herbal product and 
still disintegrate within a reasonable length of time, less 
Table 3. Results of physical and physicochemical tests of Formulation 5 tablets.
Formulation Mean weight (g)±SD Disintegration (min)±SD
Content (%, w/w)±SD
Catechin Epicatechin
Formulation 5 0.3822±0.0014 25±1.5 92.56±0.01 89.43±0.13
SD=standard deviation
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than 10 min, is a difficult challenge and an important 
component of a successful scale-up. The disintegration 
time of Formulation 5 probably influenced the release of 
active substances. It would be useful to evaluate the use 
of disintegrants/superdisintegrants to improve the release 
time, with a view toward scale-up. However, the tablets 
disintegrated within the time limit prescribed by the 
Pharmacopoeia, and microcrystalline cellulose is itself a 
disintegrant, according to the Handbook of Pharmaceutical 
Excipients (Rowe et al., 2009).
 To provide the antidepressant effect, the EPA 
dose for a normal adult weighing 70 kg was calculated as 
80 mg per day. This value was based on the proportion of 
the body surface of the rats used in the pharmacological 
test (Roncon et al., 2011) and the body surface of an 
adult human weighing 70 kg. Therefore, the formulation 
contained 80 mg EPA in 400 mg of microparticles. For 
the other formulations it was not possible to use 400 mg 
of microparticles, and therefore the dose was divided into 
two tablets with 40 mg EPA each.
 The drug manufacturing process and the 
formulation components used can influence dissolution 
and bioavailability. Tablets obtained by DC may display 
different in vitro and in vivo behavior. Dissolution testing 
is universally used in the development, production, and 
quality assurance of oral solid-dosage forms. During this 
testing, the dosage form is immersed in a flowing aqueous 
medium and the concentration of the drug released in the 
medium is measured at set time intervals, using techniques 
such as HPLC. The dissolution behavior of drugs is a 
critical quality attribute for oral solid-dosage forms, since 
in almost all cases their therapeutic efficacy depends on 
this behavior (Windbergs et al., 2009; Souza et al., 2011).
The tablets obtained from Formulation 5 were slightly 
yellowish, round, flat, and free of foreign material (Figure 
1).
 Figure 2 shows scanning electron micrographs 
(SEM) of the spray-dried extract powder (microparticles) 
and the microparticles in Formulation 5, showing that 
the particles are spherical, and remain intact before and 
after compression. Spherical particles are a common 
result of the spray-drying process, and this shape is 
associated with adequate flowability and bulk density 
(Chaves et al., 2009).
Figure 1. Tablets produced from Formulation 5 (200 mg 
microparticles containing 40 mg EPA, 170 mg microcrystalline 
cellulose, and 10 mg lactose).
 Figure 3 shows the dissolution profiles of 
the tablets made with Formulation 5 and from EPA 
microparticles. The entire EPA content, with respect to the 
chemical markers catechin and epicatechin, was released 
from the tablets over a period of 120 min. The release from 
the microparticles occurred within 60 min.
 We observed the same dissolution profile for both 
the microparticles and the tablets. However, the tablets 
required a longer time to dissolve. This occurs because 
the tablets were made by compression, and they dissolve 
through a process of erosion of the matrix together with 
swelling (Pezzini et al. 2007). The microparticles undergo 
the same process, but since their contact area with the 
dissolving liquid is much greater than that of the tablets, 
the microparticles dissolve much more rapidly.
 For the conventional solid pharmaceutical dosage 
forms, a faster release of the active compounds was 
expected, but was not observed. A plausible explanation 
Figure 2. SEM micrographs of microparticles containing EPA (A) and microparticles in tablets of Formulation 5, after 
compression (B).
A B
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for this release profi le is the disintegration time of the 
tablets, because for an immediate release, a disintegration 
time less than 10 min is recommended. Because in this 
case the disintegration time is longer (25 min), the release 
occurs more slowly in the beginning. Before the fraction is 
microencapsulated it has hygroscopic characteristics and 
good solubility; however in aqueous dispersion it is hard, 
and may tend to release more slowly.
 In analyzing the results of the release profile, 
different values of n (release exponent), which 
characterizes the release mechanism were obtained. In 
the microparticles, catechin and epicatechin had n values 
of 0.4828 and 0.5428, with correlation coefficients 
of 0.9963 and 0.9982, respectively. For cylinder 
shapes, the ranges of n values are: Fickian diffusion 
(n≤0.45), non-Fickian diffusion (0.45<n<0.89) and 
transport mechanism type II (n>0.89). Therefore, the 
microparticles showed anomalous behavior, with a 
greater influence of Fickian diffusion and less relaxation 
of the polymer chains. This profile is a pseudo-first 
order, very close to Higushi model (Aulton, 2007).
 The values of n for the tablets differed from 
those for the microparticles. In the tablets, the values 
of n and the correlation coefficients for catechin and 
epicatechin were 2.95 (r=0.9863) and 2.75 (r=0.9855), 
respectively. These values indicate a classification as 
transport mechanism type II.
Figure 3. Dissolution profile of the markers catechin (Cat) 
and epicatechin (Epi) from the tablets made with Formulation 
5 and from microparticles, determined by HPLC according to 
Klein et al. (2012).
 The aqueous medium was chosen as a fi rst step in 
assessing the release of markers in the dosage form, because 
freshly purifi ed water lacks interfering attributes, i.e., has 
a pH close to neutral and contains no ions. For future 
studies, we intend to evaluate acidic media, simulating the 
environment of the gastric or even the intestinal tract.
Conclusion
 Tablets were prepared with microparticles 
containing a semipurified extract of guaraná (EPA), 
in several formulations. The composition of each 
formulation influenced the physical and chemical 
characteristics. Only one formulation displayed 
characteristics that met pharmacopoeial specifications, 
and is therefore suitable for oral administration. The 
results of the in vitro drug release may be related to the 
more-complex structure of tablets, which hinders the 
delivery of the markers more than the microparticles, 
prolonging their release rate.
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